Genus Regulatory News (GNS)

19 November 2025

Genus plc ("Genus" or the "Group")

AGM Trading Update - Strong start to the year

Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the four months ending 31 October 2025 to coincide with its AGM at 11:00am GMT this morning.

Genus has had a strong start to the year and the Board expects Group FY26 adjusted profit before tax to be modestly ahead of the midpoint of current market expectations1.

PIC trading continued to be strong with every region achieving royalty revenue and adjusted operating profit growth2. PIC performed particularly well in China with strong royalty revenue growth being a key driver.

ABS adjusted operating profit2 has been slightly lower than expected due to phasing. Management expects a step up in performance in the second half. Value Acceleration Programme Phase 3 initiatives are progressing as planned. 

Genus will announce its interim results for the six month period from 1 July 2025 to 31 December 2025 on 26 February 2026.

Jorgen Kokke, CEO of Genus, said:

"Genus has made a strong start to the year with PIC continuing to demonstrate its robust growth model. ABS profit performance has been slightly lower than expected but we expect stronger performance in the second half. We look forward to the rest of the year with confidence."

For further information please contact:

Genus plc Tel: +44 (0)1256 345 970

Jorgen Kokke, Chief Executive Officer

Andy Russell, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan Tel: +44 (0)207 466 5000

Charles Ryland; Mark Court; Toto Berger; Jamie Hooper

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS Resistant Pig is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Footnotes

1 The Company compiled consensus estimate range for Group FY26 actual currency adjusted profit before tax is £77.6m to £85.0m with an average midpoint of £80.5m, and is based upon 8 analyst estimates. These forecasts exclude any impact from the Chinese porcine joint venture formation announced on 4 September 2025.

2 In constant currency